Myasthenia gravis: an animated, cited guide

This page needs JavaScript for its animations. The outline and key answers are below, and every claim in the full version carries a numbered citation.

Not medical advice. Myasthenia Gravis Companion is an educational synthesis of published literature. It does not replace a clinician.

What is in it

What myasthenia gravis is Who gets it, the numbers, the muscles it reaches.
The neuromuscular junction One nerve impulse in slow motion, and the safety factor.
Antibodies at the junction AChR, complement, MuSK and LRP4, animated.
Weakness over a day Why muscles tire with use and recover with rest.
Diagnosis Antibodies, nerve tests, single-fibre EMG, a calculator.
MGFA class & scores MGFA classes I to V, MG-ADL and QMG, scored live.
The differential Lambert-Eaton, botulism, ALS, eye and muscle disease.
Pyridostigmine, animated Buying time at the receptor, dose by dose.
The treatment ladder From symptom relief to immunotherapy and biologics.
Thymectomy over the years The thymus, thymoma and the MGTX trial.
Complement & FcRn inhibitors The newer biologics, trial week by trial week.
Myasthenic crisis Triggers, the breathing numbers, ICU care.
Drugs that can worsen MG A cited checker: antibiotics, magnesium and more.
Nursing care Assessment, timing the doses, teaching, documentation.
Living with MG Pregnancy, surgery, exercise, vaccines, work.
Toward a cure CAR-T, B-cell targets and the evidence for each route.
History & people From Willis in 1672 to the biologics.
Flashcards, quiz and glossary Revision for students.
Sources Every reference behind the guide.

Part 3 · Treatment

Complement & FcRn inhibitors

Complement C5 inhibitors and FcRn blockers for generalised myasthenia gravis, trial week by trial week. Pick a drug, press Play and watch the junction, the MG-ADL score and the drug's effect on complement or IgG move together.

Published trial and label information only. Everything on this page reports what the trials, labels and regulators published: doses, schedules and warnings are quoted from them for education. Whether any of these drugs suits a particular person, and how it is given, are decisions for the treating neurologist with the person with MG.

Complement C5

FcRn

Show

Week

The junction is a schematic, not to scale. Filled dots are values printed in a trial paper; open dots are label, sponsor, press or congress values, or values calculated from published numbers. Lines between dots are interpolated shapes, not measurements, and dashed lines are schematic.

How big is the benefit?

Most pivotal trials met their primary endpoint (REGAIN's prespecified worst-rank analysis did not), yet the placebo arms improved too, and many drug-minus-placebo differences sit below the 2-point MG-ADL change that best predicted a person's own sense of improvement. Pick a view, then a row, to see what the number is and how it is read. Specialists disagree on how to weigh this, so both readings are shown below.

View

Bars: point estimate, drawn as points of improvement. Whiskers: published 95% confidence interval. Outlined bars: label or congress values. Dashed line: the 2-point MG-ADL threshold.

Targets, routes and labels

Newer agents

Mechanism, safety and comparisons

A reminder. Labels, approved populations and access rules differ between countries and change over time. The figures here are for understanding the evidence, not for choosing a treatment; that choice belongs with the treating clinician.